Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants.

Muňoz FM, Swamy GK, Hickman SP, Agrawal S, Piedra PA, Glenn GM, Patel N, August AM, Cho I, Fries L.

J Infect Dis. 2019 Aug 12. pii: jiz390. doi: 10.1093/infdis/jiz390. [Epub ahead of print]

PMID:
31402384
2.

A proof of concept for structure-based vaccine design targeting RSV in humans.

Crank MC, Ruckwardt TJ, Chen M, Morabito KM, Phung E, Costner PJ, Holman LA, Hickman SP, Berkowitz NM, Gordon IJ, Yamshchikov GV, Gaudinski MR, Kumar A, Chang LA, Moin SM, Hill JP, DiPiazza AT, Schwartz RM, Kueltzo L, Cooper JW, Chen P, Stein JA, Carlton K, Gall JG, Nason MC, Kwong PD, Chen GL, Mascola JR, McLellan JS, Ledgerwood JE, Graham BS; VRC 317 Study Team.

Science. 2019 Aug 2;365(6452):505-509. doi: 10.1126/science.aav9033.

PMID:
31371616
3.

A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.

August A, Glenn GM, Kpamegan E, Hickman SP, Jani D, Lu H, Thomas DN, Wen J, Piedra PA, Fries LF.

Vaccine. 2017 Jun 27;35(30):3749-3759. doi: 10.1016/j.vaccine.2017.05.045. Epub 2017 Jun 1.

4.

Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults.

Fries L, Shinde V, Stoddard JJ, Thomas DN, Kpamegan E, Lu H, Smith G, Hickman SP, Piedra P, Glenn GM.

Immun Ageing. 2017 Apr 12;14:8. doi: 10.1186/s12979-017-0090-7. eCollection 2017.

5.

Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs.

Glenn GM, Fries LF, Smith G, Kpamegan E, Lu H, Guebre-Xabier M, Hickman SP, Flyer D.

Vaccine. 2015 Nov 25;33(47):6488-92. doi: 10.1016/j.vaccine.2015.08.039. Epub 2015 Aug 28.

6.

A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.

Glenn GM, Fries LF, Thomas DN, Smith G, Kpamegan E, Lu H, Flyer D, Jani D, Hickman SP, Piedra PA.

J Infect Dis. 2016 Feb 1;213(3):411-22. doi: 10.1093/infdis/jiv406. Epub 2015 Aug 10.

PMID:
26259809
7.

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine.

Glenn GM, Smith G, Fries L, Raghunandan R, Lu H, Zhou B, Thomas DN, Hickman SP, Kpamegan E, Boddapati S, Piedra PA.

Vaccine. 2013 Jan 7;31(3):524-32. doi: 10.1016/j.vaccine.2012.11.009. Epub 2012 Nov 12.

PMID:
23153449
8.

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.

López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Allende M, Lenhard K, Pincus S, Connolly K, Raghunandan R, Smith G, Glenn G.

Vaccine. 2011 Oct 13;29(44):7826-34. doi: 10.1016/j.vaccine.2011.07.099. Epub 2011 Aug 2.

PMID:
21816199
9.

Disparity in IL-12 release in dendritic cells and macrophages in response to Mycobacterium tuberculosis is due to use of distinct TLRs.

Pompei L, Jang S, Zamlynny B, Ravikumar S, McBride A, Hickman SP, Salgame P.

J Immunol. 2007 Apr 15;178(8):5192-9.

10.

TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis.

King CG, Kobayashi T, Cejas PJ, Kim T, Yoon K, Kim GK, Chiffoleau E, Hickman SP, Walsh PT, Turka LA, Choi Y.

Nat Med. 2006 Sep;12(9):1088-92. Epub 2006 Jul 20.

PMID:
16921377
11.
12.

Homeostatic T cell proliferation as a barrier to T cell tolerance.

Hickman SP, Turka LA.

Philos Trans R Soc Lond B Biol Sci. 2005 Sep 29;360(1461):1713-21. Review.

13.

Cutting edge: a new approach to modeling early lung immunity in murine tuberculosis.

Bhatt K, Hickman SP, Salgame P.

J Immunol. 2004 Mar 1;172(5):2748-51.

Supplemental Content

Loading ...
Support Center